State of Tennessee Treasury Department Acquires 9,541 Shares of Illumina, Inc. (NASDAQ:ILMN)
State of Tennessee Treasury Department lifted its holdings in Illumina, Inc. (NASDAQ:ILMN) by 19.1% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 59,561 shares of the life sciences company’s stock after acquiring an additional 9,541 shares during the quarter. State of Tennessee Treasury Department’s holdings in Illumina were worth $16,267,000 at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Capital Research Global Investors raised its holdings in Illumina by 1.0% in the 4th quarter. Capital Research Global Investors now owns 7,986,271 shares of the life sciences company’s stock worth $2,649,365,000 after purchasing an additional 78,667 shares in the last quarter. Edgewood Management LLC raised its holdings in Illumina by 1.7% in the 1st quarter. Edgewood Management LLC now owns 4,862,068 shares of the life sciences company’s stock worth $1,327,928,000 after purchasing an additional 81,088 shares in the last quarter. Nuveen Asset Management LLC raised its holdings in Illumina by 6.6% in the 4th quarter. Nuveen Asset Management LLC now owns 2,468,093 shares of the life sciences company’s stock worth $818,732,000 after purchasing an additional 153,459 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Illumina by 1.9% in the 1st quarter. Geode Capital Management LLC now owns 2,433,358 shares of the life sciences company’s stock worth $663,379,000 after buying an additional 45,092 shares during the period. Finally, Norges Bank purchased a new stake in shares of Illumina in the 4th quarter worth about $647,840,000. Institutional investors own 89.88% of the company’s stock.
In other Illumina news, SVP Susan H. Tousi sold 600 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $375.00, for a total transaction of $225,000.00. Following the sale, the senior vice president now owns 47,154 shares in the company, valued at approximately $17,682,750. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Robert P. Ragusa sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $340.76, for a total transaction of $1,703,800.00. Following the sale, the senior vice president now owns 17,020 shares in the company, valued at approximately $5,799,735.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 37,128 shares of company stock worth $11,980,537. 0.38% of the stock is owned by company insiders.
Shares of NASDAQ:ILMN traded down $5.92 during trading on Friday, hitting $360.33. The company’s stock had a trading volume of 159,954 shares, compared to its average volume of 940,706. The company has a 50-day moving average of $348.24 and a 200-day moving average of $310.53. Illumina, Inc. has a 12 month low of $196.78 and a 12 month high of $380.76. The company has a debt-to-equity ratio of 0.29, a current ratio of 4.10 and a quick ratio of 3.74. The firm has a market cap of $53.84 billion, a price-to-earnings ratio of 57.44, a P/E/G ratio of 5.32 and a beta of 0.98.
Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.64 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.39. Illumina had a net margin of 26.48% and a return on equity of 21.78%. The firm had revenue of $859.00 million for the quarter, compared to analysts’ expectations of $857.92 million. During the same quarter in the prior year, the business earned $1.60 EPS. The business’s quarterly revenue was up 1.5% on a year-over-year basis. As a group, research analysts anticipate that Illumina, Inc. will post 6.13 earnings per share for the current year.
Illumina Company Profile
Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.
See Also: What is a management fee?
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.